This CTD dossier owner and manufacturer specializes in oncology medications, with a focus on providing high-quality products that meet international pharmaceutical standards. They operate dedicated oncology units certified under both EU GMP and WHO GMP guidelines to ensure consistent quality across their range of products. Their key therapy areas likely revolve around cancer treatment, and they offer various dosage forms to address diverse patient needs. The company is committed to regulatory compliance, working closely with local and international bodies to maintain approvals for all their medications.

This pharmaceutical company specializes in the development and production of a wide range of generic and branded medications. Their manufacturing facility, located in an excise-free zone, is WHO-GMP certified and adheres to MHRA UK and TGA standards. They offer various dosage forms, including tablets, capsules, oral liquids, dry syrups, parenterals, MDIs, powders, and ointments. The company focuses on several key therapy areas such as antibiotics, anti-inflammatories, cardiovascular medications, anti-diabetic drugs, oncology products, and vitamins. They export their products to regions including Central Asia and the Caucasus.

This CTD dossier owner and manufacturer focuses on providing high-quality oncology drugs to over 20 countries worldwide. With more than two decades of experience, they specialize in manufacturing sterile oncology dosage forms, including liquid vials, lyophilized formulations, and complex NDDS-based products. Their product portfolio includes over 35 products targeting various solid tumors and hematological malignancies, with a commitment to palliative care formulations as well. They prioritize research and development, particularly in advanced lyophilized, liposomal, and nanoparticle-based drug delivery systems. Their manufacturing facilities adhere to strict GMP certifications, ensuring product quality and safety. Key therapy areas include oncology, with a focus on solid tumors and hematological malignancies. Principal dosage forms include liquid vials, lyophilized formulations, and complex NDDS (New Drug Delivery Systems) based products. The company emphasizes partnerships with academia, healthcare institutions, and the local community to drive research and development efforts.